EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Kidney Disease: The Forgotten Legacy of Type 1 Diabetes

Merlin C Thomas, Sophia Zoungas iD, Nordin M J Hanssen iD, Sybil A McAuley iD, Mark E Cooper iD

Diabetes Care · 01.08.2025 · 48 (8) · 1299-1308

DOI: 10.2337/dci25-0028 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes Care, online erschienen am 06.06.2025. Verfasst von Merlin C Thomas und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes, School of Translational Medicine, Monash University, Melbourne, Australia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Diabetic Nephropathies. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 98 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 1 diabetes is associated with a progressive decline in kidney function. With improved survival, more individuals with type 1 diabetes are reaching an age where irreversible loss of kidney function can impact health and clinical outcomes. Although current standard of care has markedly reduced the incidence of fast-progressing kidney disease characterized by heavy albuminuria, and improved patient survival, these same interventions have not slowed kidney decline in most patients. An urgent need remains to develop a different foundational approach to type 1 diabetes with early kidney protection considered as important as glucose control. Toward this goal, a number of new renoprotective strategies have emerged over the last decade, including glucagon-like peptide 1 receptor agonists, aldosterone antagonists, and sodium–glucose cotransporter 2 inhibitors. For each therapy unequivocal activity has been demonstrated in patients with type 2 diabetes and kidney disease, which has prompted some clinicians to use agents off-label in patients with type 1 diabetes, so pressing is their need. However, before such important benefits can be translated to patients with type 1 diabetes, the risk of serious adverse effects must be carefully considered and the balance of efficacy and safety verified in clinical trials. In this review we consider the potential role of adjunctive therapy in type 1 diabetes in improving kidney outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Diabetic NephropathiesHumansHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsMineralocorticoid Receptor Antagonists

Substanzen

Hypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsMineralocorticoid Receptor Antagonists

Autor:innen und Institutionen

  • Department of Diabetes, School of Translational Medicine, Monash University, Melbourne, Australia.
  • School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
  • Department of Endocrinology and Diabetes, Alfred Health, Melbourne, Australia.
  • Diabeter Centrum Amsterdam, Internal and Vascular Medicine, Amsterdam UMC, Meibergdreef, Amsterdam, the Netherlands.

ORCID-Profile: Sophia Zoungas, Nordin M J Hanssen, Sybil A McAuley, Mark E Cooper

Zitieren

APA

Thomas, M. C., Zoungas, S., Hanssen, N. M. J., McAuley, S. A., & Cooper, M. E. (2025). Kidney Disease: The Forgotten Legacy of Type 1 Diabetes. Diabetes Care, 48(8), 1299-1308. https://doi.org/10.2337/dci25-0028

Vancouver

Thomas MC, Zoungas S, Hanssen NMJ, McAuley SA, Cooper ME. Kidney Disease: The Forgotten Legacy of Type 1 Diabetes. Diabetes Care. 2025;48(8):1299-1308. doi:10.2337/dci25-0028

BibTeX
@article{Thomas2025,
  author = {Thomas, Merlin C and Zoungas, Sophia and Hanssen, Nordin M J and McAuley, Sybil A and Cooper, Mark E},
  title = {Kidney Disease: The Forgotten Legacy of Type 1 Diabetes},
  journal = {Diabetes Care},
  year = {2025},
  volume = {48},
  number = {8},
  pages = {1299--1308},
  doi = {10.2337/dci25-0028}
}
Kostenlos starten →